Cover Image
市場調查報告書

Aurigene Discovery Technologies Limited - 產品平台分析

Aurigene Discovery Technologies Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 271849
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Aurigene Discovery Technologies Limited - 產品平台分析 Aurigene Discovery Technologies Limited - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 48 Pages
簡介

Aurigene Discovery Technologies Limited 正在開發小分子及胜肽治療藥。該公司具有獨家綜合性藥物開發設備,用以製造針對腫瘤及發炎疾病的製品。

本報告提供Aurigene Discovery Technologies Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Aurigene Discovery Technologies Limited 基本資料

Aurigene Discovery Technologies Limited 概要

  • 主要資訊
  • 企業資料

Aurigene Discovery Technologies Limited :R&D概要

  • 主要的治療範圍

Aurigene Discovery Technologies Limited :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Aurigene Discovery Technologies Limited :開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Aurigene Discovery Technologies Limited :藥物簡介▼AUR-012

  • Drug to Inhibit Bruton's Tyrosine Kinase for Inflammation
  • Small Molecule to Agonize for ROR-Gamma for Inflammation
  • Small Molecule to Inhibit DHODH for Oncology and Inflammation
  • Small Molecule to Inhibit FabI for Bacterial Infections
  • Small Molecule to Inhibit NAMPT for Pancreatic Cancer
  • AU-2439
  • Immune Check-Point Pathway Program
  • Small Molecule to Inhibit EZH2 for Oncology
  • Small Molecule to Inhibit IRAK4 for Oncology
  • Small Molecule to Inhibit Matriptase for Infectious Diseases and Osteoarthritis

Aurigene Discovery Technologies 按Limited :開發平台分析▼標的

  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Aurigene Discovery Technologies Limited :最近的開發平台趨勢

Aurigene Discovery Technologies Limited :暫停中的計劃

Aurigene Discovery Technologies Limited :總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07999CDB

Summary

Global Markets Direct's, 'Aurigene Discovery Technologies Limited - Product Pipeline Review - 2016', provides an overview of the Aurigene Discovery Technologies Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Aurigene Discovery Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Aurigene Discovery Technologies Limited
  • The report provides overview of Aurigene Discovery Technologies Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Aurigene Discovery Technologies Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Aurigene Discovery Technologies Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Aurigene Discovery Technologies Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Aurigene Discovery Technologies Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aurigene Discovery Technologies Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Aurigene Discovery Technologies Limited Snapshot
    • Aurigene Discovery Technologies Limited Overview
    • Key Information
    • Key Facts
  • Aurigene Discovery Technologies Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Aurigene Discovery Technologies Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Aurigene Discovery Technologies Limited - Pipeline Products Glance
    • Aurigene Discovery Technologies Limited - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Aurigene Discovery Technologies Limited - Drug Profiles
    • AUR-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Target Fab Pathway for Gram Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEA-16
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AU-1702014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AU-4869
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CA-170
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CA-4948
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit EZH2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TIM-3 and PDL-1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AU-2439
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit CDK9 and BET for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit MALT-1 for Oncology and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit TDO and IDO for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK7 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit K-RAS for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aurigene Discovery Technologies Limited - Pipeline Analysis
    • Aurigene Discovery Technologies Limited - Pipeline Products by Target
    • Aurigene Discovery Technologies Limited - Pipeline Products by Route of Administration
    • Aurigene Discovery Technologies Limited - Pipeline Products by Molecule Type
    • Aurigene Discovery Technologies Limited - Pipeline Products by Mechanism of Action
  • Aurigene Discovery Technologies Limited - Recent Pipeline Updates
  • Aurigene Discovery Technologies Limited - Dormant Projects
  • Aurigene Discovery Technologies Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Aurigene Discovery Technologies Limited, Key Information
  • Aurigene Discovery Technologies Limited, Key Facts
  • Aurigene Discovery Technologies Limited - Pipeline by Indication, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Stage of Development, 2016
  • Aurigene Discovery Technologies Limited - Monotherapy Products in Pipeline, 2016
  • Aurigene Discovery Technologies Limited - Partnered Products in Pipeline, 2016
  • Aurigene Discovery Technologies Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Aurigene Discovery Technologies Limited - Out-Licensed Products in Pipeline, 2016
  • Aurigene Discovery Technologies Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Aurigene Discovery Technologies Limited - IND/CTA Filed, 2016
  • Aurigene Discovery Technologies Limited - Preclinical, 2016
  • Aurigene Discovery Technologies Limited - Discovery, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Target, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Route of Administration, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Molecule Type, 2016
  • Aurigene Discovery Technologies Limited - Pipeline Products by Mechanism of Action, 2016
  • Aurigene Discovery Technologies Limited - Recent Pipeline Updates, 2016
  • Aurigene Discovery Technologies Limited - Dormant Developmental Projects,2016
  • Aurigene Discovery Technologies Limited, Other Locations
  • Aurigene Discovery Technologies Limited, Subsidiaries

List of Figures

  • Aurigene Discovery Technologies Limited - Pipeline by Top 10 Indication, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Stage of Development, 2016
  • Aurigene Discovery Technologies Limited - Monotherapy Products in Pipeline, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Top 10 Target, 2016
  • Aurigene Discovery Technologies Limited - Pipeline by Molecule Type, 2016
  • Aurigene Discovery Technologies Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top